Literature DB >> 3941552

Late thrombosis of the Björk-Shiley tilting disc valve in the tricuspid position. Thrombolytic treatment with streptokinase.

D Boskovic, I Elezovic, D Boskovic, N Simin, Z Rolovic, V Josipovic.   

Abstract

The main complication after implantation of a Björk-Shiley tilting disc valve in the tricuspid position is late thrombotic obstruction. Of 28 patients with tricuspid valve replacement (16 with mitral, aortic, and tricuspid valve replacement; 12 with mitral and tricuspid valve replacement), with a mean follow-up of 5.2 years, seven (25%) had thrombosis of the tricuspid prosthesis. Three patients had a recurrent thrombotic malfunction, for a total of ten thrombotic malfunctions in 146 patient-years, a rate of 6.8 per 100 patient-years. Thrombosis occurred late in all patients. Clinical deterioration presented with signs of congestive heart failure. In all patients the click of the tricuspid prosthesis was not audible and new diastolic or systolic murmurs were. The diagnosis was confirmed with cineradiography and bidimensional echocardiography (immobile disc, diminished opening angle of the disc). Thrombolytic treatment with streptokinase was used in all seven patients. Two patients required 12 hours of therapy and five patients, 24 hours. Thrombolytic treatment was monitored by the thrombin time. Complete regression of clinical, cineradiographic, and echocardiographic signs fo thrombosis was seen in all seven patients during the first 24 hours of therapy. There were no bleeding complications. In one patient clinical signs of mild pulmonary embolism occurred and were confirmed with chest radiographs. Follow-up, after successful treatment, extends from 4 to 30 months (mean 16.5 months). In four patients long-term results are excellent: There have been no clinical, cineradiographic, or echocardiographic signs of rethrombosis of the tricuspid prosthesis during the follow-up. Rethrombosis of the tricuspid prosthesis was observed in three patients 4, 7, and 14 months after initial treatment with streptokinase. Repeat thrombolytic treatment with streptokinase was successful in all three of these patients. Our experience with streptokinase treatment of thrombosis of tricuspid Björk-Shiley prostheses indicates that this form of treatment should always be applied before surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941552

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Long-term results of porcine bioprostheses in the tricuspid position.

Authors:  K Kuwaki; K Komatsu; K Morishita; M Tsukamoto; T Abe
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

2.  Nonsurgical correction for thrombosis of a St. Jude Medical tricuspid prosthesis: report of a case.

Authors:  S Aoyagi; S Suzuki; K Oishi; T Hashino; S Nakata; H Toshima
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

3.  Tricuspid valve replacement with the St. Jude Medical valve.

Authors:  S Aoyagi; Y Nishi; T Kawara; A Oryoji; H Hara; K Kosuga; K Ohishi
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

4.  Thrombolytic treatment for massive thrombosis of prosthetic cardiac valves.

Authors:  F Guerrero López; G Vázquez Mata; A Reina Toral; I Rodríguez Bailón; E Fernández Mondéjar; P Aranegui Lasuen
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Early thrombosis of a tricuspid valve prosthesis: two-dimensional echocardiographic demonstration.

Authors:  V Paolillo; M Villani; Z Krajcer; G Cerrone; M Morea; M Casaccia
Journal:  Tex Heart Inst J       Date:  1988

6.  Results of tricuspid valve replacement for nonrheumatic and noninfective disease.

Authors:  A Renzulli; I Goudevenos; P Santé; S Naik; P R Behl; A Blesovsky
Journal:  Tex Heart Inst J       Date:  1990

7.  Ten-year experience of tricuspid valve replacement with the St. Jude medical valve.

Authors:  Xiliang Zhu; Yi Luo; Eryong Zhang; Qi An; Xijun Xiao; Li Dong; Yingqiang Guo; Ke Dian; Zhong Wu
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.